Calcipotriene: profile and news

Topical therapies show promise for Psoriasis  06 Mar 2006
A combination of calcipotriene and betamethasone dipropionate, a vitamin D analogue and a potent corticosteroid, was recently approved by the FDA in an ... - News-Medical.net,

FDA Approves Taclonex (Calcipotriene/Betamethasone Dipropionate) ...  Jan 10, 2006
Taclonex is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of psoriasis vulgaris ... - DG News

FDA Approves Taclonex(R) - Once Daily Therapy for Treatment of ...  Jan 10, 2006
Taclonex(R) is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of psoriasis ... - PR Newswire (press release),

LEO and Foamix to Develop Two New Medicated Foams for the ...  Nov 28, 2005
The foams will be based on LEO Pharma's proprietary Calcipotriene (Vitamin D3) compound and its combination with specific steroids, which represent the ... - Biotech Intelligence (press release),

Leo and Foamix to collaborate on psoriasis foams  Nov 29, 2005
...psoriasis. The foams will be based on Leo Pharma's proprietary calcipotriene compound and its combination with specific steroids. ... - Pharmaceutical Business Review

Enters into co-promotion agreement with Bristol-Myers Squibb for ...  Oct 3, 2005
Dovonex® (calcipotriene), a treatment for mild to moderate psoriasis is currently marketed in the United States by Bristol-Myers Squibb under license from LEO ... - Biotechnology Investment Today (Press Release),

Sexual Issues Related to Psoriasis  Jul 20, 2005
Vitamin D compounds, such as calcipotriene (Dovonex), and retinoids, such as tarazotene (Tazorac), are rarely used for genital psoriasis because they can cause ... - 7Online.com <**results**>

Treating Psoriasis at Its Surface  Jun 29, 2005
...effects. Calcipotriene, a synthetic form of vitamin D, reduces the excess production of skin cells associated with psoriasis. It ... - 7Online.com,

Connetics Reports Highlights of 2005 Analyst and Investor Day ...  Apr 14, 2005
This will be the first product developed in Connetics' newest generation foam. -- Discussing Calcipotriene VersaFoam-EF Trials: Connetics anticipates ... - Genetic Engineering News,

Connetics Presents 11 Scientific Posters at American Academy of ...  Feb 17, 2005
...presented on OLUX(R), including one study that demonstrates the synergistic effect of the concomitant application of OLUX and calcipotriene ointment, which may ... - PharmaLive.com (press release),